1) Salami SS, Tosoian JJ, Nallandhighal S, Jones TA Jr, Brockman S, Elkhoury FF, Bazzi S, Plouffe KR, Siddiqui J, Liu CJ, Kunju LP, Morgan TM, Natarajan S, Boonstra PS, Sumida L, Tomlins SA, Udager AM, Sisk AE Jr, Marks LS, Palapattu GS. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. 2020 Jul 3:S0302-2838(20)30470-X. doi: 10.1016/j.eururo.2020.06.041. Online ahead of print. PMID: 32631746
2) Kinnaird A, Sharma V, Chuang R, Priester A, Tran E, Barsa DE, Delfin M, Kwan L, Sisk A, Felker E, Marks LS. Risk of Prostate Cancer after a Negative MRI-Guided Biopsy. J Urol. 2020 Jul 2:101097JU0000000000001232. doi: 10.1097/JU.0000000000001232. Online ahead of print. PMID: 32614257
3) Marks LS, Natarajan S. RE: Prostate Cancer Detection Rate of Free-hand versus 3D Template Mapping Biopsy Using an MRI/Ultrasound Fusion Device in Biopsy-Naïve Men. J Urol. 2020 May 4:101097JU0000000000001124. doi: 10.1097/JU.0000000000001124. Online ahead of print. PMID: 32364836
4) Al Hussein Al Awamlh B, Marks LS, Sonn GA, Natarajan S, Fan RE, Gross MD, Mauer E, Banerjee S, Hectors S, Carlsson S, Margolis DJ, Hu JC. Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. Urol Oncol. 2020 Jul;38(7):637.e9-637.e15. doi: 10.1016/j.urolonc.2020.03.019. Epub 2020 Apr 17. PMID: 32307327
5) Marks LS, Kinnaird A. Editorial Comment. J Urol. 2020 May;203(5):924. doi: 10.1097/JU.0000000000000692.02. Epub 2020 Feb 20. PMID: 32077800
6) Guorgui J, Kinnaird A, Jayadevan R, Priester AM, Arnold CW, Marks LS. An Electronic Form for Reporting Results of Targeted Prostate Biopsy: Urology Integrated Diagnostic Report (Uro-IDR). Urology. 2020 Apr;138:188-193. doi: 10.1016/j.urology.2020.01.015. Epub 2020 Jan 21. PMID: 31978527
7) Gross MD, Marks LS, Sonn GA, Green DA, Wang GJ, Shoag JE, Cabezon E, Margolis DJ, Robinson BD, Hu JC. Reply by Authors. J Urol. 2020 Mar;203(3):536. doi: 10.1097/JU.0000000000000534.02. Epub 2019 Dec 2. PMID: 31789578
8) Zhou SR, Priester AM, Jayadevan R, Johnson DC, Yang JJ, Ballon J, Natarajan S, Marks LS. Using spatial tracking with magnetic resonance imaging/ultrasound-guided biopsy to identify unilateral prostate cancer. BJU Int. 2020 Mar;125(3):399-406. doi: 10.1111/bju.14943. Epub 2019 Nov 25. PMID: 31680423
9) Kinnaird A, Marks LS. Editorial Comment. J Urol. 2020 Jan;203(1):106-107. doi: 10.1097/01.JU.0000604048.44926.a2. Epub 2019 Oct 16. PMID: 31618155
10) Zhou SR, Chang E, Patankar A, Huang J, Marks LS, Natarajan S. Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men. J Urol. 2020 Apr;203(4):699-705. doi: 10.1097/JU.0000000000000587. Epub 2019 Oct 9. PMID: 31596671
11) Jayadevan R, Felker ER, Kwan L, Barsa DE, Zhang H, Sisk AE, Delfin M, Marks LS. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer. JAMA Netw Open. 2019 Sep 4;2(9):e1911019. doi: 10.1001/jamanetworkopen.2019.11019. PMID: 31509206
12) Gross MD, Marks LS, Sonn GA, Green DA, Wang GJ, Shoag JE, Cabezon E, Margolis DJ, Robinson BD, Hu JC. Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study. J Urol. 2020 Mar;203(3):530-536. doi: 10.1097/JU.0000000000000534. Epub 2019 Sep 10. PMID: 31502942
13) Felker ER, Raman SS, Lu DSK, Tuttle M, Margolis DJ, ElKhoury FF, Sayre J, Marks LS. Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation. AJR Am J Roentgenol. 2019 Dec;213(6):1253-1258. doi: 10.2214/AJR.19.21637. Epub 2019 Jul 30. PMID: 31361529
14) Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S, Marks LS. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surg. 2019 Sep 1;154(9):811-818. doi: 10.1001/jamasurg.2019.1734. PMID: 31188412
15) Natarajan S, Bajgiran AM, Shakeri S, Sisk A, Felker ER, Raman SS, Marks LS, Reiter RE. Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. Cancer. 2019 Sep 1;125(17):2955-2964. doi: 10.1002/cncr.32170. Epub 2019 May 1. PMID: 31042322
16) Karow D, Lu DSK, White N, Marks LS. Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer. AJR Am J Roentgenol. 2019 Aug;213(2):365-370. doi: 10.2214/AJR.18.20836. Epub 2019 Apr 30. PMID: 31039011
17) Jayadevan R, Zhou S, Priester AM, Delfin M, Marks LS. Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy. J Vis Exp. 2019 Apr 9;(146). doi: 10.3791/59231. PMID: 31033955
18) Simopoulos DN, Sisk AE Jr, Priester A, Felker ER, Kwan L, Delfin MK, Reiter RE, Marks LS. Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage. BJU Int. 2019 Aug;124(2):275-281. doi: 10.1111/bju.14691. Epub 2019 Feb 24. PMID: 30694605
